| Literature DB >> 35623070 |
Myeongseok Koh1, Min-Chan Kim2, Jin Seok Jang1.
Abstract
ABSTRACT: We compared the prevalence of adenoma and cancerous colon polyps in patients undergoing endoscopic removal or gastric surgery for gastric adenoma or gastric cancer and in healthy individuals.The medical records of 707 patients with gastric neoplasm and 798 age- and sex-matched healthy subjects were retrospectively analyzed between January 2010 and July 2018. The clinicopathological characteristics, prevalence of colorectal neoplasm diagnosed by colonoscopy, and risk factors for colorectal polyps were also investigated.When comparing the two groups, the prevalence of overall colorectal polyps and its distribution was not different between the two groups (54.0% vs.49.5%, P = .079), whereas, the number of colon polyps (1.20 ± 1.71 vs 0.99 ± 1.54, P = .015) and the maximal size (3.53 ± 6.14 vs 2.08 ± 2.88, P < .001) were significantly larger in the gastric neoplasm group. The prevalence of advanced colon adenoma was significantly higher in the gastric neoplasm group (10.7% vs 3.8%, P < .001). Risk factors such as elevated glucose levels and the presence of gastric neoplasm were related to the prevalence of all colon polyps. The presence of gastric neoplasm is an important risk factor for advanced colon polyps.Patients with gastric neoplasms had a significantly higher prevalence of advanced colon adenoma. Advanced colon adenoma is associated with the chain from benign adenomas through malignant altered adenomas to advanced colon cancer. Thus, patients with gastric neoplasm are regarded as a high-risk group for colorectal cancer and are recommended for screening colonoscopy at the time of diagnosis.Entities:
Mesh:
Year: 2022 PMID: 35623070 PMCID: PMC9276267 DOI: 10.1097/MD.0000000000029308
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Baseline characteristics in the study group and the control group.
| Study group (n = 707) | Control group (n = 798) | ||
| Age (yr, mean ± SD) | 58.85 ± 9.93 | 57.53 ± 6.12 | .456 |
| Sex, male:female | 494: 213 | 550: 248 | .690 |
| BMI (kg/m2; mean ± SD) | 24.22 ± 10.27 | 24.30 ± 3.18 | .835 |
|
| |||
| Total cholesterol (mg/dL; mean ± SD) | 181.32 ± 87.08 | 205.13 ± 36.93 |
|
| Low density lipoprotein (mg/dL; mean ± SD) | 115.66 ± 37.26 | 126.14 ± 34.45 |
|
| High density lipoprotein (mg/dL; mean ± SD) | 56.39 ± 25.69 | 56.39 ± 14.91 | 1.000 |
| Glucose (mg/dL; mean ± SD) | 108.31 ± 32.13 | 92.71 ± 19.85 |
|
| CEA (ng/mL; mean ± SD) | 3.04 ± 6.94 | 2.05 ± 1.39 |
|
| CA 19–9 (U/mL; mean ± SD) | 12.75 ± 55.98 | 9.68 ± 11.26 | .312 |
|
| |||
| Colon polyp n (%) | .079 | ||
| YES | 382 (54.0%) | 395 (49.5%) | |
| NO | 325(46.0%) | 403 (50.5%) | |
| Colon polyp, (Number., mean ± SD) | 1.20 ± 1.71 | 0.99 ± 1.54 |
|
| Colon polyp site, n (%) | .361 | ||
| Right | 172 (24.3%) | 173 (21.7%) | |
| Left | 102 (14.4%) | 108 (13.5%) | |
| Both | 108 (15.3%) | 114 (14.3%) | |
| Maximum size of colon polyp, (mm, mean ± SD) | 3.53 ± 6.14 | 2.08 ± 2.88 |
|
| Advanced adenoma, n (%) |
| ||
| YES | 76 (10.7%) | 30 (3.8%) | |
| NO | 631 (89.3%) | 768 (96.2%) | |
| Polyp pathology, n (%) |
| ||
| Tubular adenoma | 303 (42.9%) | 292 (36.6%) | |
| Tubulovillous/villous adenoma | 19 (2.7%) | 10 (1.3%) | |
| Serrated adenoma | 15 (2.1%) | 16 (2.0%) | |
| Adenocarcinoma | 14 (2.0%) | 1 (0.1%) | |
BMI = body mass index, CA 19–9 = carbohydrate antigen 19–9, CEA = carcinoemcryonic antigen, SD = standard deviation.
Figure 1Prevalence of all colon polyps, advanced adenoma, and adenocarcinomas in the gastric neoplasm(study group) and control group. The prevalence of advanced adenoma and adenocarcinoma was significantly higher.
Univariate analysis of risk factors for colon polyps and for advanced colonic adenoma in the whole group (including control).
| All polyps | Advanced colon adenoma | |||||
| Absence (n = 728) | Presence (n = 777) | Absence (n = 1399) | Presence (n = 106) | |||
| Age (yr, mean ± SD) | 58.14 ± 8.19 | 59.19 ± 8.05 |
| 58.60 ± 8.13 | 59.77 ± 8.11 | .152 |
| Male, Sex | 503 (69.1%) | 541 (69.6%) | .823 | 962 (68.8%) | 82 (77.4%) | .066 |
| BMI |
| .143 | ||||
| < 23 | 256 (36.5%) | 215 (29.5%) | 447 (33.4%) | 24 (26.4%) | ||
| 23 to < 25 | 176 (25.1%) | 215 (29.5%) | 369 (27.6%) | 22 (24.2%) | ||
| ≥ 25 | 270 (38.5%) | 298 (40.9%) | 523 (39.1%) | 45 (49.5%) | ||
| Serum total cholesterol | .768 | .094 | ||||
| < 200 mg/dL | 402 (57.3%) | 414 (57.4%) | 402 (57.3%) | 414 (57.4%) | ||
| 200 – 240mg/dL | 218 (31.1%) | 231 (32.0%) | 218 (31.1%) | 231 (32.0%) | ||
| ≥ 240 mg/dL | 82 (11.7%) | 76 (10.5%) | 82 (11.7%) | 76 (10.5%) | ||
| Low density lipoprotein (mg/dL; mean ± SD) | 124.27 ± 35.06 | 125.37 ± 34.91 | .634 | 124.70 ± 35.15 | 127.31 ± 31.32 | .637 |
| High density lipoprotein (mg/dL; mean ± SD) | 57.50 ± 17.81 | 55.28 ± 15.64 |
| 56.56 ± 16.53 | 52.74 ± 21.38 | .141 |
| Glucose (mg/dL; mean ± SD) | 96.62 ± 25.22 | 100.41 ± 27.16 |
| 98.05 ± 25.16 | 107.00 ± 38.88 |
|
| CEA (ng/mL; mean ± SD) | 2.29 ± 2.72 | 2.62 ± 5.84 | .262 | 2.43 ± 4.73 | 2.76 ± 2.13 | .537 |
| CA 19–9 (U/mL; mean ± SD) | 9.35 ± 11.94 | 12.13 ± 46.99 | .301 | 10.32 ± 32.29 | 17.17 ± 59.97 | .195 |
| Gastric pathology |
|
| ||||
| Control | 403 (55.4%) | 395 (50.8%) | 768 (55.2%) | 30 (28.3%) | ||
| Adenoma | 90 (12.4%) | 115 (14.8%) | 181 (13.0%) | 21 (19.8%) | ||
| EGC | 156 (21.4%) | 201 (25.8%) | 319 (22.8%) | 38 (35.8%) | ||
| AGC | 79 (10.9%) | 66 (8.5%) | 131 (9.4%) | 17 (16.0%) | ||
AGC = advanced gastric cancer, BMI = body mass index, CA 19–9 = carbohydrate antigen 19–9, CEA = carcinoemcryonic antigen, CI = confidence interval, EGC = early gastric cancer, SD = standard deviation.
Multivariate logistic regression analysis risk factors for colon polyps and advanced adenoma in the whole group (including control).
| All polyps | Advanced colon adenoma | |||
| Odds ratio (95% CI) | Odds ratio (95% CI) | |||
| Age | 0.990 (0.970–1.010) | .333 | 1.014 (0.987- 1.041) | .320 |
| Sex | .561 | .169 | ||
| Male | Reference | Reference | ||
| Female | 1.101 (0.820–1.477) | 0.687 (0.403 - 1.173) | ||
| BMI | .977 | |||
| <25 | Reference | |||
| ≥ 25 | 0.996 (0.754 -1.316) | |||
| High density lipoprotein | 1.006 (0.998–1.015) | .152 | ||
| Glucose | 1.007 (1.001 - 1.014) |
| 1.005 (0.998 - 1.011) | .193 |
| Gastric pathology |
|
| ||
| Control | Reference | Reference | ||
| Study group | 1.570 (1.000 - 2.464) | 2.788 (1.718 - 4.524) |
BMI = body mass index.
Univariate analysis of risk factors for colon polyps and for advanced colonic adenoma in the study group.
| All polyps | Advanced colon adenoma | |||||
| Absence (n = 325) | Presence (n = 382) | Absence (n = 631) | Presence (n = 76) | |||
| Age (yr, mean ± SD) | 57.90 ± 10.28 | 59.67 ± 9.56 | .019 | 58.68 ± 10.05 | 60.34 ± 8.77 | .167 |
| Male, Sex | 235 (72.1%) | 259 (68.0%) | .236 | 436 (69.1%) | 58 (76.3%) | .197 |
| BMI | .913 | .187 | ||||
| < 23 | 95 (31.7%) | 110 (33.1%) | 190 (33.3%) | 15 (33.1%) | ||
| 23 to < 25 | 87 (29.0%) | 96 (28.9%) | 167 (29.2%) | 16 (26.2%) | ||
| ≥ 25 | 118 (39.3%) | 126 (38.0%) | 214 (37.5%) | 30 (49.2%) | ||
| Serum total cholesterol | .201 | .136 | ||||
| < 200 mg/dL | 215 (71.7%) | 245 (75.4%) | 407 (72.4%) | 53 (84.1%) | ||
| 200 – 240mg/dL | 67 (22.3%) | 70 (21.5%) | 128 (22.8%) | 9 (14.3%) | ||
| ≥ 240 mg/dL | 18 (6.0%) | 10 (3.1%) | 27 (4.8%) | 1 (1.6%) | ||
| Low density lipoprotein (mg/dL; mean ± SD) | 118.50 ± 40.10 | 113.48 ± 35.08 | .473 | 115.79 ± 37.71 | 114.58 ± 34.60 | .915 |
| High density lipoprotein (mg/dL; mean ± SD) | 57.14 ± 31.73 | 55.75 ± 19.42 | .762 | 55.82 ± 24.54 | 61.83 ± 35.81 | .446 |
| Glucose (mg/dL; mean ± SD) | 108.17 ± 29.87 | 108.41 ± 33.73 | .934 | 107.63 ± 30.30 | 114.00 ± 44.58 | .183 |
| CEA (ng/mL; mean ± SD) | 2.86 ± 3.97 | 3.20 ± 8.76 | .577 | 3.08 ± 7.32 | 2.70 ± 1.98 | .702 |
| CA 19–9 (U/mL; mean ± SD) | 9.29 ± 12.01 | 15.53 ± 73.36 | .391 | 11.76 ± 52.88 | 20.22 ± 75.66 | .400 |
| Gastric pathology | .064 | .869 | ||||
| Adenoma | 90 (27.6%) | 115 (30.1%) | 181 (28.7%) | 21 (27.6%) | ||
| EGC | 156 (48.1%) | 201 (52.8%) | 319 (50.6%) | 38 (50%) | ||
| AGC | 79 (24.2%) | 66 (17.0%) | 131 (20.8%) | 17 (22.4%) | ||
AGC = advanced gastric cancer, BMI = body mass index, CA 19–9 = carbohydrate antigen 19–9, CEA = carcinoemcryonic antigen, EGC = early gastric cancer, SD = standard deviation.